SRR1343481
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.362
- MYOGENESIS+0.309
- SPERMATOGENESIS+0.263
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.257
- APICAL_JUNCTION+0.215
- CHOLESTEROL_HOMEOSTASIS+0.155
- APICAL_SURFACE+0.147
- FATTY_ACID_METABOLISM+0.145
- PANCREAS_BETA_CELLS+0.135
- OXIDATIVE_PHOSPHORYLATION+0.124
Top 10 suppressed
- MYC_TARGETS_V1-0.521
- IL6_JAK_STAT3_SIGNALING-0.504
- G2M_CHECKPOINT-0.461
- E2F_TARGETS-0.448
- ALLOGRAFT_REJECTION-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- INTERFERON_ALPHA_RESPONSE-0.424
- PROTEIN_SECRETION-0.409
- TGF_BETA_SIGNALING-0.398
- ANDROGEN_RESPONSE-0.376
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1337564 | GTEX | — | 0.944 |
| 2 | SRR1332796 | GTEX | — | 0.944 |
| 3 | SRR1480988 | GTEX | — | 0.934 |
| 4 | SRR1333930 | GTEX | — | 0.933 |
| 5 | SRR1439807 | GTEX | — | 0.931 |
| 6 | SRR1323746 | GTEX | — | 0.929 |
| 7 | SRR1082262 | GTEX | — | 0.929 |
| 8 | SRR1419187 | GTEX | — | 0.928 |
| 9 | SRR1444580 | GTEX | — | 0.926 |
| 10 | SRR1486097 | GTEX | — | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.362 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.309 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.263 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.257 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.215 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.155 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.147 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.145 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.135 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.124 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.104 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.084 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.044 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.027 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.025 | Idelalisib | — uncovered |